title: No-carrier-added (NCA) N-(3-[18F]fluoropropyl)-N-norbuprenorphine and N-(3-[18F]fluoropropyl)-N-nordiprenorphine--synthesis, anatomical distribution in mice and rats, and tomographic studies in a baboon.
abstract: N-(3-Fluoropropyl)-N-norbuprenorphine (3a) and N-(3-fluoropropyl)-N-nordiprenorphine (4a) were synthesized by N-alkylation of norbuprenorphine (1) and nordiprenorphine (2) with 1-bromo-3-fluoropropane. The corresponding no-carrier-added (NCA) N-(3-[18F]fluoropropyl)-N-norbuprenorphine (3b) and N-(3-[18F]fluoropropyl)-N-nordiprenorphine (4b) were synthesized by N-alkylation of 1 and 2 with NCA 1-[18F]fluoro-3-iodopropane in a synthesis time of approximately 100 min from end of bombardment (EOB) with an overall radiochemical yield of approximately 15% (EOB) and a mass of 2-3 nmol. In vitro studies indicate that in the absence of sodium chloride, compounds 3a, 4a, N-propyl-N-norbuprenorphine (5), buprenorphine and diprenorphine are reasonably comparable in binding affinity for opioid receptors. In the presence of 100 mM sodium chloride, however, compounds 3a, 4a and 5, are clearly less potent than buprenorphine and diprenorphine. The anatomical distribution study of compound 3b in mice shows radioactivity accumulating in bone, indicating that in vivo defluorination may have occurred. Rat studies of both compounds 3b and 4b indicate the specific distribution of these two radioligands within certain cortical and subcortical regions of rat brain. However, the absolute uptake of compound 4b in rat brain was only half that of compound 3b. PET studies of 3b in a baboon revealed specific binding of compound 3b in striatum and cerebellum. At 1 h after injection, ratios of specific/non-specific binding of 3b in striatum and cerebellum of a baboon were 1.9 and 1.7 respectively.
authors.affiliation: Chemistry Department, Brookhaven National Laboratory, Upton, NY 11973.
authors.forename: L Q
authors.initials: LQ
authors.lastname: Bai
authors.forename: R R
authors.initials: RR
authors.lastname: Teng
authors.forename: C Y
authors.initials: CY
authors.lastname: Shiue
authors.forename: A P
authors.initials: AP
authors.lastname: Wolf
authors.forename: S L
authors.initials: SL
authors.lastname: Dewey
authors.forename: M J
authors.initials: MJ
authors.lastname: Holland
authors.forename: E J
authors.initials: EJ
authors.lastname: Simon
mesh_terms: D000818:Animals; D001921:Brain / Q000000981:diagnostic imaging; D002047:Buprenorphine / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000493:pharmacokinetics; D004174:Diprenorphine / Q000031:analogs & derivatives / Q000138:chemical synthesis* / Q000493:pharmacokinetics; D005260:Female; D005462:Fluorine Radioisotopes; D051379:Mice; D009019:Morphinans / Q000138:chemical synthesis*; D010215:Papio; D051381:Rats; D011919:Rats, Inbred Strains; D011957:Receptors, Opioid / Q000378:metabolism; D014018:Tissue Distribution; D014055:Tomography, Emission-Computed
chemical_list: D005462:Fluorine Radioisotopes; D009019:Morphinans; D011957:Receptors, Opioid; C063368:N-(3-fluoropropyl)-N-nordiprenorphine; C064201:N-(3-fluoropropyl)-N-norbuprenorphine; D004174:Diprenorphine; D002047:Buprenorphine